America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy‘.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
What are the key benefits of AOH1996 compared to other cancer treatments currently available?
**Interview with Dr. Linda Malkas on the Development of AOH1996**
**Editor:** Welcome, Dr. Malkas. Thank you for joining us today to discuss the exciting new developments in cancer treatment at City of Hope. Could you tell us a bit about the mechanism of action for the drug AOH1996?
**Dr. Malkas:** Thank you for having me. AOH1996 is a groundbreaking molecule that specifically targets the cancer variant of a protein known as PCNA (Proliferating Cell Nuclear Antigen). You can think of PCNA as a hub in an airport; it plays a critical role in DNA replication and, consequently, tumor growth. By disrupting this function, our drug effectively targets and kills cancer cells while sparing healthy cells.
**Editor:** That is fascinating! How does the analogy of an airport hub relate to how AOH1996 operates against cancer cells?
**Dr. Malkas:** To use the airport analogy, PCNA is like a busy airport terminal, facilitating various flights—representing cellular activities—necessary for cell division. In cancer cells, the PCNA hub is altered, allowing for uncontrolled growth. AOH1996 acts like a snowstorm that can ground all flights, specifically those associated with cancer cell proliferation, thereby halting their spread.
**Editor:** You mentioned that AOH1996 has shown effectiveness across various cancer types in clinical research. Which cancers are we talking about?
**Dr. Malkas:** Yes, we have seen promising results in treating several types of cancers, including breast, prostate, brain, ovarian, cervical, skin, and lung cancers. In our studies, we tested AOH1996 on over 70 different cancer cell lines, and the findings indicate selective toxicity toward malignant cells.
**Editor:** What are the next steps now that the findings have been published?
**Dr. Malkas:** The immediate next step is to commence clinical trials in humans. We aim to evaluate the safety and efficacy of AOH1996 in a clinical setting. Our research thus far has been encouraging, and we are optimistic about the potential outcomes.
**Editor:** How long do you anticipate it may take before AOH1996 could be available to patients?
**Dr. Malkas:** While I would love to provide a precise timeline, bringing a drug to market involves numerous phases, including extensive clinical trials which can take several years. However, our team is dedicated to accelerating this process as much as possible while ensuring patient safety and rigorous scientific validation.
**Editor:** Thank you, Dr. Malkas, for this insightful discussion. It’s encouraging to see such innovative treatments on the horizon for cancer patients.
**Dr. Malkas:** Thank you for having me. It’s a privilege to share our work, and we hope these advancements will significantly impact cancer treatment in the future.
